SUMMARY Peripheral and axial bone mass and fracture incidence were studied in a group of 104 postmenopausal patients with rheumatoid arthritis (RA). Patients were divided into noncortiscosteroid and low dose corticosteroid treated groups after elimination of patients with concomitant disease or therapy which might affect bone mass. Results were compared with those obtained in controls matched for age and sex. Bone mass at the distal radius was significantly reduced compared with that of controls in both patient groups. Axial bone mass, however, was normal in both treatment groups, non-corticosteroid treated patients having even a significantly higher bone mass than controls (p<0-05) and corticosteroid treated patients (p<0.05). Fracture incidence (vertebral and femoral neck) was significantly (p<0*01) higher in corticosteroid treated patients than in the non-corticosteroid treated group. The mean lumbar bone mineral content and the body weight of the fracture group were significantly lower than in the controls. There were no significant differences in biochemical markers of bone turnover between the RA groups.
be multifactorial, with the duration and severity of the disease process, the administration of corticosteroids systemically, age, sex, and menopausal state all having an influence, it is necessary to control as many of these factors as possible in order to obtain unbiased results.
In some studies a more severe degree of bone loss was found in RA patients treated with corticosteroids,8 13 14 but other studies did not confirm this.7 9 1 12 15 16 Numerous studies confirm the deleterious effects of corticosteroids on bone, especially trabecular bone, and the musculoskeletal system in other diseases. [17] [18] [19] We have, therefore, prospectively studied bone mass, both peripheral and axial, and fracture incidence in a group of postmenopausal patients with RA. We have divided them into a noncorticosteroid treated group and a corticosteroid treated group after elimination of all possible interfering factors, and we have compared the results obtained in these groups with those from control group matched for sex, age, and menopausal status.
Patients and methods
Bone mineral content (BMC) was measured in the radius and the spine in 104 postmenopausal women with classical or definite RA (American Rheumatism Association criteria20) and in 43 postmenopausal controls. The patients with rheumatoid arthritis were consecutive admissions to our rheumatology unit for adjustment of therapy.
At the time of the bone mineral content measurement all patients received a check of their metabolic bone state, including biochemical (serum and urinary) parameters of calcium metabolism as previously described,2' and one x ray of both hands and the spine.
Bone mineral content (BMC) at the forearm (distal radius 1/3 left side) was measured by means of the Norland Cameron 1251 single photon absorptiometry method,'7 while lumbar BMC (L2-L3-L4) was measured by means of the Novo Lab 22 '53Gd dual photon absorptiometry method. '8 The patients with RA were divided into two groups according to whether or not they were being treated with corticosteroids systemically at the time of the evaluation or had been during the past disease course for at least six months.
Almost all patients were receiving non-steroidal anti-inflammatory drugs and all of them had been treated with one 
Results
Characteristics of patients and controls are summarised in Table 1 . In the corticosteroid treated group there were no differences between patients treated with corticosteroids in the past and those under treatment at the time of the measurement, so they could be regarded as one entity. Sixty four per cent of the patients in the corticosteroid treated group were still on steroids at the time of the investigation. The mean dose of prednisone equivalent was 8-9 (SD 6.0) mg/day, and the mean duration of corticosteroid treatment was 4-7 (SD 4.1) years. The corticosteroid treated patients had a significantly longer disease course than the non-corticosteroid treated patients, and their body weight was significantly lower than that of the controls. Table 2 provides an overview of the serum and urinary parameters of bone metabolism in both groups. As can be seen from this table, there were no significant differences between the two groups in biochemical parameters of bone turnover.
The results of the bone mineral content measurements at the radius, distal 1/3, both trabecular and cortical site, and at the lumbar spine, are given in Table 3 .
In In the control group BMC at the radius 3 cm and 8 cm was significantly correlated with BMC of the axial skeleton (r=0.548, p<0-001 and r=0-452, p<0-005 respectively). In the RA group this correlation was found only in the corticosteroid treated group, though at a lower level of significance (p<O.05).
In none of the RA groups was there a correlation between lumbar BMC and biochemical markers of bone turnover. There was-also no correlation between duration of corticosteroid treatment and lumbar BMC.
Fractures of vertebrae or femoral neck due to minimal trauma occurred in 9-6% of the RA group as a whole. The percentage of patients in the corticosteroid treated group who sustained fractures (16-3%) was greater than the percentage in the noncorticosteroid treated group (3.6%). 
Discussion
This study conducted in a homogeneous group of postmenopausal patients with RA shows that rheumatoid arthritis does not alter the bone mineral content in the spine, but that corticosteroids even in low dose affect the spine and fracture incidence. The bone mineral content of the peripheral skeleton near the arthritic joints is significantly reduced in RA with no additional effect of steroid treatment. The latter findings agree with previous reports of a lower bone mass at the metacarpals or at the radius in RA,S8 1112 and with our previous longitudinal group.bmj.com on November 7, 2017 -Published by http://ard.bmj.com/ Downloaded from data,4 and those of Virtama et al,12 which showed that corticosteroid treated patients did not lose more bone from the peripheral skeleton, indicating that inflammation and disuse due to pain and destruction are the main factors involved in peripheral bone loss in RA.
The finding of a significantly increased lumbar BMC in non-corticosteroid treated RA cases is interesting but difficult to explain. It is possible that non-steroidal anti-inflammatory drugs, because of their prostaglandin synthetase inhibiting effect, interfere with bone resorption. It has been shown by Mundy that in vitro prostaglandin E2 stimulates bone resorption."9 Differences in lumbar BMC between the two RA groups disappear, however, when a case control study of comparable disease duration in both groups is made. So the difference in lumbar BMC between corticosteroid treated and non-corticosteroid treated patients was due to a difference in disease duration rather than to the corticosteroid treatment.
On the other hand, we observed a significantly higher incidence of fractures in the steroid treated patients. The explanation for this contradictory observation is not clear, but it is possible that corticosteroids alter the quality of the bone rather than the quantity of bone mineral. Another possibility is that the expected low BMC of the spine in steroid treated patients is masked by compression of trabeculae, secondary sclerosis of the end plates, and apophyseal osteoarthritis.
In studies using other measuring techniques, such as neutron activation, significantly lower total body calcium values were found in corticosteroid treated patients with RA which correlated with steroid dosage.13 These results, however, cannot be compared with ours since they combined men and women with RA of all ages and since 80% of the total body calcium represents peripheral cortical bone mass.
McConkey et al'6 and Hajiroussou and Webley," using a subjective density grading of x rays of the spine, did not find significant differences between patients with RA receiving low dose corticosteroids or non-corticosteroid treatment. As in our study, McConkey noted that vertebral fracture was seen only in the corticosteroid treated patients. Saville and Kharmosh, on the other hand, found no greater incidence of spinal fractures in those treated with corticosteroids.7
The mechanism by which corticosteroids may alter bone quality is not known. Low doses (5 24 In this study 25-hydroxyvitamin D levels were normal, as were serum levels of immunoreactive PTH. The latter observation is in contrast with the finding of Fucik et al, who found an increased PTH level in corticosteroid treated patients.25
Despite the evidence presented in this paper on the lack of effect of corticosteroids on lumbar bone mineral content in RA compared with the effect on normal controls we think that the increased incidence of pathological fractures in patients receiving corticosteroids for RA and other conditions26 establishes the deleterious effect of this drug on bone quality in some patients. Since the incidence of steroid induced osteoporosis is less than 50% there is a need to identify the patients at risk and apply preventive measures. This study points to the patient at risk being the postmenopausal women, especially the slender one. 27 Frumar et al showed that obesity protected against excess calcium loss and bone resorption,28 indicating a relation between body weight, circulating oestrogens, and urinary calcium loss. In the postmenopausal women androstenedione from the adrenal gland becomes converted to oestradiol in the subcutaneous fat. In the presence of exogenous corticosteroids the pituitaryhypothalamic axis is suppressed, resulting in diminished output of androstenedione from the adrenal gland and thus lower serum oestrogen levels. 
